Abstract
This study investigated the expression of the N-ras oncogene in routinely processed tissue sections from 133 patients with squamous cell carcinoma of the head and neck (SCCHN) by immunohistochemistryusing anti-N-ras monoclonal antibody. N-ras expression was present in 67 of 133 (49.67%) cases. There was a highly significant correlation between N-ras expression and clinical stage of disease (P=0.003). This study confirmed that overexpression of the N-ras oncogene is common in SCCHN and that it may be an important event in the late stage of disease.
Similar content being viewed by others
References
Agnantis N.J, Petraki C., Markoulatos P, and Spandidos DA: Immunohistochemical study of the ras oncogene expression in human breast lesions. Anticancer Res 6:1157–1160. 1986.
Armitage P and Doll R: The age distribution of cancer and a multi-stage theory of carcinogenesis. Brit J Cancer 8:1–12, 1954.
Balmain A, Ramsden M, Bowden GT, and Smith J: Activation of the mouse cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature 307: 658–660, 1984.
Barbacid M: Ras genes. [Review] Ann Review Biochem 56:779–827, 1987.
Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49:4682–4689, 1989.
Candlish W. Kerr IB, and Simpson HW: Immunocytochemical demonstration and significance of ras p21 family oncogene product in benign and malignant breast disease. J Pathol 150:163–167. 1986.
Chang SE, Bhatia P, Johnson NW, Morgan PR, McCormick F, Young B, und Hiorns L: Ras mutations in United Kingdom examples of oral malignancies are infrequent. Int J Cancer 48:409–412. 1991.
DeBortoli ME, Abou-Issa H, Haley BE, and Cho-Chung YS: Amplified expression of p21 ras protein in hormone-dependent mammary carcinomas of humans and rodents. Biochem Biophys Res Commun 127:699–709. 1985.
Fearon ER, and Volgestein B, A gene model for colorectal tumorigenesis. [Review] Cell 61:757–767. 1990.
Field JK: Oncogenes and tumor-suppressor genes in squamous cell carcinoma of the head and neck. [Review] Oral Oncol Eur J Cancer 28B: 67–76. 1992.
Field JK, and Spandidos DA: Expression of oncogenes in human tumours with special reference to the head and neck region. [Review] J Oral Pathol 16:97–107. 1987.
Hirano T, Steele PE, and Gluckmam JL: Low incidence of point mutation at codon 12 of K-ras proto-oncogene in squamous cell carcinoma of the upper aerodigestive tract. Ann Otol Rhinol Laryngol 100:597–599. 1991.
McDonald JS, Jones H, Pavelic ZP, Pavelic LJ, Stambrook PJ, and Gluckman JL: Immimohistochemical detection of the Hras. K-ras. and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 23: 342–346. 1994.
Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, Pass H, Minna JD, and Gazdar AF: Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999–5002. 1991.
Ohuchi N, Thor A, Page DL, Horan Hand P, Halter SA, and Schlom J: Expression of the 21.000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues. Cancer Res 46: 2511–2519. 1986.
Palejwala S, and Goldsmith LT: Detection of Ki-ras protooncogene protein by a specific monoclonal antibody. Biotechniques 11:606–608, 1991.
Palejwala S, and Goldsmith LT: Ovarian expression of cellular Ki-ras p21 varies with physiological status. Proc Natl Acad Sci USA 89:4202–4206, 1992.
Pavelic ZP, Ghukman JL, Gapany M, Reising J, Craven. JM, Kelley DJ, Pavelic LJ, Gapany S, Biddinger P, and Stambrook PJ: Improved immimohistochemical detection of p53 protein in paraffin embedded tissues reveals elevated levels in most head and neck and lung carcinomas: correlation with clinicopathological parameters. Anticancer Res 12:1389–1394. 1992.
Pavelic ZP, Pavelic LJ, Kuvelkar R, and Gapany S: High cmyc expression in benign colorectal lesions correlates with the degree of dysplasia. Anticancer Res 12:171–176. 1992.
Pavelic ZP, Pavelic LJ, Lower EE, Gapany M, Gapany S, Barker EA, and Preisler HD: c-myc. c-erbB2, and Ki-67 expression in normal breast tissue, invasive and non-invasive breast carcinoma. Cancer Res 52:2597–2602. 1992.
Pavelic ZP, Portugal LG, Gootee MJ, Stambrook PJ, Smith C, Mugge RE, Pavelic LJ, Wilson K, Buncher RC, Li Y-Q, McDonald JS, and Gluckman JL: Retrieval of p53 protein in paraffin-embedded head and neck tumor tissues. Arch Otolaryngol Head Neck Surg 119:1206–1209. 1993.
Quintanilla M, Brown K, Ramsden M, and Balmain A: Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322:78–80, 1986.
Rumshy G, Carter RL, and Gusterson BA: Low incidence of ras oncogene activation in human squamous cell carcinomas. Br J Cancer 61:365–368, 1990.
Saranath D, Chang SE, Bhoite LT, Panchal RG, Kerr IB, Mehta AR, Johnson, NW, and Deo MG: High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India. Br J Cancer 63:573–578. 1991.
Sheng ZM, Barrois M, Klijanienko J, Micheau C, Richard JM, and Riou G: Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. Br J Cancer 62:398–404. 1990.
Shi SR, Key ME, and Kalra KL: Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741–748. 1991.
Salomon E, Borrow J and Goddard AD: Chromosome aberrations and cancer. [Review] Sci 254:1153–1160, 1991.
Whittaker JL, Walker RA, and Varley JM: Differential expression of cellular oncogenes in benign and malignant human breast tissue. Int J Cancer38:651–655, 1986.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McDonald, J.S., Wilson, K.M., Gartside, P. et al. Immunohistochemical expression of N-ras oncogene is a late event in head and neck carcinomas. Pathol. Oncol. Res. 2, 30–33 (1996). https://doi.org/10.1007/BF02893944
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893944